These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Magnetic nanoparticles-based diagnostics and theranostics. Cohen Y; Shoushan SY Curr Opin Biotechnol; 2013 Aug; 24(4):672-81. PubMed ID: 23415743 [TBL] [Abstract][Full Text] [Related]
24. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845 [TBL] [Abstract][Full Text] [Related]
25. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. Arsenault F; Beauregard JM; Pouliot F Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893 [TBL] [Abstract][Full Text] [Related]
26. Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer. Andrew J; Ezra-Manicum AL; Witika BA EJNMMI Radiopharm Chem; 2024 Aug; 9(1):62. PubMed ID: 39180599 [TBL] [Abstract][Full Text] [Related]
27. Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications. Azizi M; Dianat-Moghadam H; Salehi R; Farshbaf M; Iyengar D; Sau S; Iyer AK; Valizadeh H; Mehrmohammadi M; Hamblin MR Adv Funct Mater; 2020 May; 30(19):. PubMed ID: 34093104 [TBL] [Abstract][Full Text] [Related]
28. A Review on Novel Applications of Nanotechnology in the Management of Prostate Cancer. Khanam A; Singh G; Narwal S; Chopra B; Dhingra AK Curr Drug Deliv; 2024; 21(9):1161-1179. PubMed ID: 37888818 [TBL] [Abstract][Full Text] [Related]
29. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984 [TBL] [Abstract][Full Text] [Related]
30. New Advances in Nanotechnology-Based Diagnosis and Therapeutics for Breast Cancer: An Assessment of Active-Targeting Inorganic Nanoplatforms. Falagan-Lotsch P; Grzincic EM; Murphy CJ Bioconjug Chem; 2017 Jan; 28(1):135-152. PubMed ID: 27973767 [TBL] [Abstract][Full Text] [Related]
31. Tumor-targeted and multi-stimuli responsive drug delivery system for near-infrared light induced chemo-phototherapy and photoacoustic tomography. Feng Q; Zhang Y; Zhang W; Shan X; Yuan Y; Zhang H; Hou L; Zhang Z Acta Biomater; 2016 Jul; 38():129-42. PubMed ID: 27090593 [TBL] [Abstract][Full Text] [Related]
32. Unique roles of nanotechnology in medicine and cancer-II. Alam F; Naim M; Aziz M; Yadav N Indian J Cancer; 2015; 52(1):1-9. PubMed ID: 26837958 [TBL] [Abstract][Full Text] [Related]
33. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032 [TBL] [Abstract][Full Text] [Related]
34. Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Hosoya H; Dobroff AS; Driessen WH; Cristini V; Brinker LM; Staquicini FI; Cardó-Vila M; D'Angelo S; Ferrara F; Proneth B; Lin YS; Dunphy DR; Dogra P; Melancon MP; Stafford RJ; Miyazono K; Gelovani JG; Kataoka K; Brinker CJ; Sidman RL; Arap W; Pasqualini R Proc Natl Acad Sci U S A; 2016 Feb; 113(7):1877-82. PubMed ID: 26839407 [TBL] [Abstract][Full Text] [Related]
35. Smart multifunctional drug delivery towards anticancer therapy harmonized in mesoporous nanoparticles. Baek S; Singh RK; Khanal D; Patel KD; Lee EJ; Leong KW; Chrzanowski W; Kim HW Nanoscale; 2015 Sep; 7(34):14191-216. PubMed ID: 26260245 [TBL] [Abstract][Full Text] [Related]
36. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970 [TBL] [Abstract][Full Text] [Related]
37. Nanotechnology for targeted cancer therapy. Wang MD; Shin DM; Simons JW; Nie S Expert Rev Anticancer Ther; 2007 Jun; 7(6):833-7. PubMed ID: 17555393 [TBL] [Abstract][Full Text] [Related]
38. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743 [TBL] [Abstract][Full Text] [Related]
39. New aspects of molecular imaging in prostate cancer. Ceci F; Castellucci P; Cerci JJ; Fanti S Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565 [TBL] [Abstract][Full Text] [Related]
40. Engineered Polymer Nanoplatforms for Targeted Tumor Cells and Controlled Release Cargos to Enhance Cancer Treatment. Wang Z; Tang L; Mu Q; Che S; Sun Y; Bai L; Luo Y; Yang Y; Yu M; Yu Z Curr Med Chem; 2021; 28(31):6395-6410. PubMed ID: 33634752 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]